[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100538549":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":43,"centralContacts":47,"locations":53,"responsibleParty":71,"collaborators":42,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":76,"sex":82,"minAge":83,"maxAge":42,"enrollmentInfo":84,"targetDuration":42,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":42,"overallStatus":55,"whyStopped":42,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"The University of Hong Kong","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Chemotherapy and surgery arm","EXPERIMENTAL","Patients receive platinum-based chemotherapy with or without bevacizumab, and then undergo cytoreductive operation, for the first recurrence of EOC.",[13,14,15,16],"Procedure: Carboplatin or cisplatin","Drug: Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar","Drug: Bevacizumab or biosimilar","Procedure: Cytoreductive surgery",[18,25,32,38],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"PROCEDURE","Carboplatin or cisplatin","Carboplatin of cisplatin for 3-6 cycles",[9],[24],"Paraplatin or Platinol",{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","Paclitaxel, gemcitabine or liposomal doxorubicin with or without bevacizumab or biosimilar","Paclitaxel, gemcitabine or liposomal doxorubicin, for 3-6 cycles",[9],[31],"Taxol, Gemzar, Caelyx",{"type":26,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"Bevacizumab or biosimilar","Optional",[9],[37],"Avastin or mvasi",{"type":19,"name":39,"description":40,"armGroupLabels":41,"otherNames":42},"Cytoreductive surgery","Cytoreductive surgery after chemotherapy",[9],null,[44],{"name":45,"affiliation":5,"role":46},"Ka Yu Tse","PRINCIPAL_INVESTIGATOR",[48],{"name":49,"role":50,"phone":51,"phoneExt":42,"email":52},"Lesley Lau","CONTACT","852-22554265","lsk382@hku.hk",[54],{"facility":5,"status":55,"city":56,"state":42,"zip":42,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"RECRUITING","Hong Kong","HK",{"type":59,"coordinates":60},"Point",[61,62],114.17469,22.27832,{"lat":62,"lon":61},[65,67,69],{"name":49,"role":50,"phone":66,"phoneExt":42,"email":42},"852-22554518",{"name":45,"role":50,"phone":51,"phoneExt":42,"email":68},"tseky@hku.hk",{"name":70,"role":46,"phone":42,"phoneExt":42,"email":42},"Ka Yu Tse, MBBS, PhD",{"type":46,"investigatorFullName":72,"investigatorTitle":73,"investigatorAffiliation":5,"oldNameTitle":42,"oldOrganization":42},"Dr. Ka-Yu Tse","Clinical Associate Professor","100538549","secondary-interval-cytoreductive-surgery-in-platinum-sensitive-recurrent-epithelial-ovarian-cancer-100538549",false,"NCT06292286","Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer","Secondary Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer Patients - a Pilot Study","SCENIC","Inclusion Criteria:\n\n* Histologically diagnosed EOC, fallopian tube or primary peritoneal carcinoma\n* \\>= 3 cycles of platinum-based chemotherapy, with or without bevacizumab and \u002F or PARPi, at primary setting\n* Platinum-free interval should be \\>=6 months from the last dose of platinum-based chemotherapy\n* Upfront SCR not feasible\n* Patients should have Eastern Cooperative Oncology Group (ECOG) performance score 0 to 2 within 28 days prior to recruitment.\n* Patients must have adequate bone marrow, renal, hepatic and neurological function within 28 days prior to the start of treatment.\n\nExclusion Criteria:\n\n* Non-epithelial or borderline tumors are excluded\n* Patients who have with concurrent malignancy within five years (except for basal or squamous cell skin cancer, in-situ breast cancer, stage 1a grade 1-2 endometrioid endometrial carcinoma without lymphovascular invasion) are excluded.\n* Patients using more than one line of chemotherapy are excluded.\n* Patients who have platinum-resistant or refractory recurrence are excluded.\n* Patients having second relapse or beyond are excluded.\n* Patients who have contraindications to operation, e.g., unresolved thrombocytopenia, bowel obstruction in the last 4 weeks prior to enrolment","FEMALE","18 Years",{"count":85,"type":86},18,"ESTIMATED","INTERVENTIONAL",[89],"NA","About 80% of advanced ovarian cancer patients recurred in 2-3 years. Secondary cytoreduction benefits selected patients who have high chance of complete resection. Whether secondary interval surgery can be used at recurrence is not known.",[92],"Recurrent Ovarian Carcinoma","2025-06-06",{"date":95,"type":96},"2025-06-11","ACTUAL",{"date":98,"type":96},"2023-11-01",{"date":100,"type":86},"2026-12-31",{"name":5,"class":6},1]